全文获取类型
收费全文 | 9515篇 |
免费 | 614篇 |
国内免费 | 75篇 |
专业分类
耳鼻咽喉 | 159篇 |
儿科学 | 243篇 |
妇产科学 | 282篇 |
基础医学 | 1068篇 |
口腔科学 | 141篇 |
临床医学 | 881篇 |
内科学 | 2481篇 |
皮肤病学 | 134篇 |
神经病学 | 996篇 |
特种医学 | 289篇 |
外科学 | 1621篇 |
综合类 | 90篇 |
一般理论 | 2篇 |
预防医学 | 618篇 |
眼科学 | 77篇 |
药学 | 524篇 |
1篇 | |
中国医学 | 30篇 |
肿瘤学 | 567篇 |
出版年
2024年 | 12篇 |
2023年 | 78篇 |
2022年 | 209篇 |
2021年 | 369篇 |
2020年 | 193篇 |
2019年 | 322篇 |
2018年 | 338篇 |
2017年 | 229篇 |
2016年 | 282篇 |
2015年 | 337篇 |
2014年 | 415篇 |
2013年 | 540篇 |
2012年 | 809篇 |
2011年 | 799篇 |
2010年 | 407篇 |
2009年 | 357篇 |
2008年 | 628篇 |
2007年 | 674篇 |
2006年 | 600篇 |
2005年 | 570篇 |
2004年 | 522篇 |
2003年 | 501篇 |
2002年 | 391篇 |
2001年 | 69篇 |
2000年 | 56篇 |
1999年 | 48篇 |
1998年 | 58篇 |
1997年 | 33篇 |
1996年 | 35篇 |
1995年 | 36篇 |
1994年 | 21篇 |
1993年 | 24篇 |
1992年 | 21篇 |
1991年 | 21篇 |
1990年 | 15篇 |
1989年 | 19篇 |
1988年 | 10篇 |
1987年 | 7篇 |
1985年 | 14篇 |
1984年 | 10篇 |
1983年 | 16篇 |
1982年 | 14篇 |
1981年 | 11篇 |
1980年 | 8篇 |
1977年 | 7篇 |
1976年 | 6篇 |
1974年 | 6篇 |
1973年 | 5篇 |
1971年 | 10篇 |
1970年 | 5篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
81.
Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia. 总被引:9,自引:0,他引:9
Emmanuel Raffoux Philippe Rousselot J?el Poupon Marie-Thérèse Daniel Bruno Cassinat Richard Delarue Anne-Laure Taksin Delphine Réa Agnès Buzyn Annick Tibi Geneviève Lebbé Patricia Cimerman Christine Chomienne Jean-Paul Fermand Hugues de Thé Laurent Degos Olivier Hermine Hervé Dombret 《Journal of clinical oncology》2003,21(12):2326-2334
PURPOSE: Arsenic trioxide (ATO) is capable of inducing a high hematologic response rate in patients with relapsed acute promyelocytic leukemia (APL). Preclinical observations have indicated that all-trans-retinoic acid (ATRA) may strongly enhance the response to ATO. PATIENTS AND METHODS: Between 1998 and 2001, we conducted a randomized study of ATO alone versus ATO plus ATRA in 20 patients with relapsed APL, all previously treated with ATRA-containing chemotherapy. The primary objective was to demonstrate a significant reduction in the time necessary to obtain a complete remission (CR) in the ATO/ATRA group compared with the ATO group. Secondary objectives were safety and molecular response. RESULTS: The CR rate after one ATO with or without ATRA induction cycle was 80%. Clinical and pharmacokinetic observations indicated that the main mechanism of action of ATO in vivo was the induction of APL cell differentiation. Hematologic and molecular response, time necessary to reach CR, and outcome were comparable in both treatment groups. Of 16 CR patients, three patients who reached a molecular remission after one induction cycle had all received chemotherapy for a treatment-induced hyperleukocytosis. Three additional patients who received further additional ATO with or without ATRA cycles converted later to molecular negativity. CONCLUSION: ATRA did not seem to significantly improve the response to ATO in patients relapsing from APL. Other potential combinations, including ATO plus chemotherapy, have to be tested. 相似文献
82.
Thierry Andre Philippe Colin Christophe Louvet Erik Gamelin Olivier Bouche Emmanuel Achille Nicolas Colbert Catherine Boaziz Pascal Piedbois Nicole Tubiana-Mathieu Arnaud Boutan-Laroze Michel Flesch Marc Buyse Aimery de Gramont 《Journal of clinical oncology》2003,21(15):2896-2903
PURPOSE: This randomized, 2 x 2 factorial study compared a semimonthly (LVFU2) with a monthly (FULV) regimen of fluorouracil and leucovorin and 24 versus 36 weeks of each regimen as adjuvant treatment of patients with stage II (Dukes' B2) and III (Dukes' C) colon cancer. PATIENTS AND METHODS: LVFU2 was administered semi-monthly for 2 consecutive days as dl- or l-leucovorin (200 or 100 mg/m2, respectively) as a 2-hour infusion, followed by a 400 mg/m2 FU bolus and 600 mg/m2 of FU as a 22-hour continuous infusion. FULV was administered monthly for 5 consecutive days as a 15-minute infusion of dl- or l-leucovorin, followed by 400 mg/m2 of FU as a 15-minute infusion. RESULTS: A total of 905 patients were randomly assigned. The median follow-up was 41 months. Disease-free survival was similar between the LVFU2 and FULV groups (127 v 124 events; hazard ratio [HR] = 1.04; P =.74) and between 24 and 36 weeks of therapy (128 v 123 events; HR = 0.94; P =.63). Analysis of overall survival showed a slight excess in the number of deaths in LVFU2 compared with FULV (73 v 59), but this difference was not statistically significant (HR = 1.26; 95% confidence interval, 0.90 to 1.78; P =.18). The most commonly observed grade 3 to 4 toxicities were neutropenia, diarrhea, and mucositis. Toxicities were significantly lower in the LVFU2 group (all toxicities, P <.001). CONCLUSION: Our data confirm that LVFU2 is less toxic than FULV. At a median follow-up of 41 months, no statistically significant difference could be detected in disease-free or overall survival between the treatment groups or treatment durations. 相似文献
83.
CT-based delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, NCIC,RTOG consensus guidelines. 总被引:25,自引:0,他引:25
Vincent Grégoire Peter Levendag Kian K Ang Jacques Bernier Marijel Braaksma Volker Budach Cliff Chao Emmanuel Coche Jay S Cooper Guy Cosnard Avraham Eisbruch Samy El-Sayed Bahman Emami Cai Grau Marc Hamoir Nancy Lee Philippe Maingon Karin Muller Hervé Reychler 《Radiotherapy and oncology》2003,69(3):227-236
BACKGROUND AND PURPOSE: The appropriate application of 3-D CRT and IMRT for HNSCC requires a standardization of the procedures for the delineation of the target volumes. Over the past few years, two proposals--the so-called Brussels guidelines from Grégoire et al., and the so-called Rotterdam guidelines from Nowak et al.--emerged from the literature for the delineation of the neck node levels. Detailed examination of these proposals however revealed some important discrepancies. MATERIALS AND METHODS: Within this framework, the Brussels and Rotterdam groups decided to review their guidelines and derive a common set of recommendations for delineation of neck node levels. This proposal was then discussed with representatives of major cooperative groups in Europe (DAHANCA, EORTC, GORTEC) and in North America (NCIC, RTOG), which, after some additional refinements, have endorsed them. The objective of the present article is to present the consensus guidelines for the delineation of the node levels in the node-negative neck. RESULTS AND CONCLUSIONS: First a short discussion of the discrepancies between the previous Brussels and the Rotterdam guidelines is presented. The general philosophy of the consensus guidelines and the methodology used to resolve the various discrepancies are then described. The consensus proposal is then presented and representative CTVs that are consistent with these guidelines are illustrated on CT sections. Last, the limitations of the consensus guidelines are discussed and some concerns about the direct applications of these guidelines to the node-positive neck and the post-operative neck are described. 相似文献
84.
Estrogen receptor negative and progesterone receptor positive primary breast cancer: Pathological characteristics and clinical outcome 总被引:9,自引:0,他引:9
Agnès Bernoux Patricia de Cremoux Christine Lainé-Bidron Emmanuel C. Martin Bernard Asselain Henri Magdelénat 《Breast cancer research and treatment》1998,49(3):219-225
The expression of estrogen (ER) and progesterone (PgR) receptors was analyzed in a retrospective series of 3000 patients who had operable primary breast cancer. Patients were stratified according to ER and PgR status and the study was focused on the two groups (ER–PgR+ and ER–PgR–) of patients whose tumors contained low levels of ER (< 15 fmol/mg protein), regarding potential response to endocrine therapy. The comparison of clinical or histological characteristics between ER–PgR+ and ER–PgR– patients was analyzed as well as the disease-related death and survival. The mean follow-up was 86.3 months. Among the 529 ER–patients, 62 were PgR+ (12%), whereas 467 were PgR– (88%). The ER–PgR+ and ER–PgR– populations represented 2% and 15.6% of the overall population, respectively. In ER– tumors, the PgR status was significantly related to: age, menopausal status, tumor size, SBR grade, and histological type, but not to the type of surgical treatment or to lymph node involvement. ER–PgR+ tumors had smaller size (64% T1 vs 43%) (p=0.004) and were more frequently grade I (28% vs 12%) than ER–PgR– ones (p < 0.001). In addition, the patients with ER–PgR+ tumors were significantly younger (49.4 years vs 58.4 years; p < 0.0001), and were more frequently premenopausal (76% vs 36%; p < 0.001). The disease-free interval and the metastasis-free survival tended to be worse for ER–PgR– than for ER–PgR+ patients, but the difference was not statistically significant at 10 years. However, a small but significant difference in overall survival, in favor of the PgR+ group, was observed between the two groups during the first 5 years (p=0.03).We conclude that in combination with ER, PgR status defines a group of patients with clinical and biological specificity, which could be considered for specific endocrine therapy. 相似文献
85.
86.
88.
89.
Laurence Veracini Dominique Grall Sébastien Schaub Stéphanie Beghelli-de la Forest Divonne Marie-Christine Etienne-Grimaldi Gérard Milano Alexandre Bozec Emmanuel Babin Anne Sudaka Juliette Thariat Ellen Van Obberghen-Schilling 《Oncotarget》2015,6(10):7570-7583
EGF receptor (EGFR) overexpression is thought to drive head and neck carcinogenesis however clinical responses to EGFR-targeting agents have been modest and alternate targets are actively sought to improve results. Src family kinases (SFKs), reported to act downstream of EGFR are among the alternative targets for which increased expression or activity in epithelial tumors is commonly associated to the dissolution of E-cadherin-based junctions and acquisition of a mesenchymal-like phenotype. Robust expression of total and activated Src was observed in advanced stage head and neck tumors (N=60) and in head and neck squamous cell carcinoma lines. In cultured cancer cells Src co-localized with E-cadherin in cell-cell junctions and its phosphorylation on Y419 was both constitutive and independent of EGFR activation. Selective inhibition of SFKs with SU6656 delocalized E-cadherin and disrupted cellular junctions without affecting E-cadherin expression and this effect was phenocopied by knockdown of Src or Yes. These findings reveal an EGFR-independent role for SFKs in the maintenance of intercellular junctions, which likely contributes to the cohesive invasion E-cadherin-positive cells in advanced tumors. Further, they highlight the need for a deeper comprehension of molecular pathways that drive collective cell invasion, in absence of mesenchymal transition, in order to combat tumor spread. 相似文献
90.